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Abstract 
Two chiral and water-soluble thiosemicarbazone-proline (H2L
1) and thiosemicarbazone-
homoproline hybrids (H2L
2) were synthesized. By reaction of H2L
1 with NiCl2∙6H2O, PdCl2 
and CuCl2∙2H2O, in ethanol the series of square-planar complexes [Ni(H2L
1)Cl]Cl∙1.3H2O 
(1∙1.3H2O), [Pd(H2L
1)Cl]Cl∙H2O (2∙H2O) and [Cu(H2L
1)Cl]Cl∙0.7H2O (3∙0.7H2O) were 
prepared, while starting from H2L
2 and CuCl2∙2H2O in methanol the complex 
[Cu(H2L
2)Cl]Cl∙H2O (4∙H2O) was obtained. The compounds have been characterized by 
elemental analysis, spectroscopic methods (IR, UV−vis and NMR spectroscopy), ESI mass 
spectrometry and single crystal X-ray crystallography (H2L
1, 1 and 2). As a solid, 1 is 
diamagnetic, while paramagnetic in methanolic solution. The effective magnetic moment of 
3.26 B.M. at room temperature indicates the change of coordination geometry from square-
planar to octahedral after dissolution. The in vitro anticancer potency of ligand precursors 
H2L
1 and H2L
2 and metal complexes 1−4 was studied in three human cancer cell lines (A549, 
CH1 and SW480) an in non-cancerous fibroblasts (NIH/3T3), and the mechanism of cell 
death was also assayed by flow cytometry. Clear-cut structure-activity relationships have 
been established. The metal ions exert marked effects in a divergent manner: copper(II) 
increases, whereas nickel(II) and palladium(II) decrease the cytotoxicity of the hybrids. The 
antiproliferative activity of H2L
1 and metal complexes 1−3 decreases in all three tumor cell 
lines in the following rank order: 3 > H2L
1 > 1 > 2. The role of square-planar geometry in the 
underlying mechanism of cytotoxicity of the metal complexes studied seems to be negligible, 
while structural modifications at the terminal amino group of thiosemicarbazide and proline 
moiety are significant for enhancing the antiproliferative activity of both hybrids and 
copper(II) complexes. 
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Introduction 
-(N)-Heterocyclic thiosemicarbazones (TSCs) are a class of highly potent inhibitors of 
ribonucleotide reductase (RNR) enzyme. 1 , 2  RNR catalyzes the reduction of all four 
ribonucleotides to their corresponding deoxyribonucleotides, and thereby provides the 
precursors needed for both synthesis and repair of DNA. Currently, the most studied 
therapeutic compound among the thiosemicarbazones is Triapine (3-aminopyridine-2-
carboxaldehyde thiosemicarbazone). It is by a factor of 1000 more potent inhibitor of hR2 
RNR activity than hydroxyurea, a clinically used RNR inhibitor. 3  Triapine has entered 
several phase II clinical trials as a chemotherapeutic agent.4 However, this investigational 
drug showed severe side effects, while only little response was observed.5 , 6 , 7 ,8  Another 
promising drug, di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC) is 
scheduled to enter clinical trials in 2016,9 but RNR is not or only in part responsible for its 
biological activity. 
 
Many thiosemicarbazones are excellent chelators for transition metal ions, such as iron(II), 
copper(II) and zinc(II), typically coordinating via X, N, S atoms, where X is the donor atom 
of the additional functional group of the aldehyde or ketone used for their preparation.10 The 
coordination of these TSCs can result in metal complexes with higher cytotoxicity than that 
of the ligand precursors. In addition, the enhanced need for the essential metal ions of cancer 
cells vs healthy cells makes the development of new chelators as anticancer agents an 
important task.11,12 Copper(II) complexes are promising anticancer agents,13 often exhibiting 
very high antiproliferative activity in vitro. In particular, copper(II) complexes with acyl 
diazine thiosemicarbazones bearing an N4-azabicyclo[3.2.2]-nonane group showed cytotoxic 
activity against colon adenocarcinoma HT-29 cells with IC50 values ranging from 0.004 to 
1.51 µM and  human acute lymphoblastic leukemia CCRF-CEM cells with IC50 values from 
0.005 to 1.16 µM.14 
 
Recently a series of copper(II)-TSC complexes has been tested for their topoisomerase IIα 
inhibition activity with the conclusion that the complexes are more potent topoisomerase IIα 
inhibitors compared to the corresponding ligand precursors. 15  One of such copper(II) 
complexes was [CuLCl], where HL = 2-pyridinealdehyde 4-N-ethylthiosemicarbazone. The 
main prerequisite for their topoisomerase IIα inhibition properties was suggested to be the 
square-planar coordination geometry of copper(II) in these complexes. 
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Despite their high cytotoxicity in vitro, low water solubility, high lipophilicity and high in 
vivo toxicity are the main disadvantages of TSC compounds as anticancer agents,16 so that 
one of the current challenges is the design of new active TSCs and their metal complexes 
with enhanced aqueous solubility17 and a priori oriented towards a cancer specific target.18 
We have shown that 2-hydroxybenzaldehyde thiosemicarbazone (STSC) can be coupled to L- 
or D-proline (Pro) leading to hybrids with enhanced aqueous solubility.19 Although these new 
systems show only moderate cytotoxic potency with IC50 values of 62 and 75 µM, 
respectively, in ovarian carcinoma CH1 cells and >100 µM in colon carcinoma SW480 cells, 
coordination of these ligands to copper(II) resulted in 13 and 5-fold increase in cytotoxicity in 
CH1 cells, based on a comparison of IC50 values, while in SW480 cells the enhancement of 
the antiproliferative activity was even higher. In both tested cell lines, L-Pro-STSC as well as 
its copper(II) complex showed slightly stronger antiproliferative activity than the compounds 
with a D-Pro moiety, yielding IC50 values of 4.6 and 5.5 µM for [Cu(L-Pro-STSC)Cl]Cl in 
CH1 and SW480 cells, respectively.19 Moreover, the preliminary data on screening the 
topoisomerase IIα inhibiting activity indicate that the square-planar copper(II) complexes 
prepared by us are indeed potential inhibitors of the topoisomerase IIα enzyme in contrast to 
the corresponding metal-free conjugates, which are devoid of such activity.  
 
The quite recently reported results19 prompted us to prepare new 2-hydroxybenzaldehyde 
thiosemicarbazones substituted at the terminal nitrogen atom to enhance the lipophilicity and 
coupled to two related - and -amino acid homologs, namely proline and homoproline. We 
anticipated that these new conjugates will form square-planar metal complexes enabling the 
elucidation of (i) the role of square-planar coordination geometry of the metal complexes in 
the underlying mechanism of antiproliferative activity, (ii) the effect of metal coordination 
and (iii) substitution at the terminal nitrogen atom of thiosemicarbazide moiety, as well as (iv) 
the effect of homologization of proline to 3-homoproline on antiproliferative activity in 
cancer cell lines. Herewith we report on the synthesis of two organic conjugates, namely 5-
methyl-2-hydroxybenzaldehyde 4-N-pyrrolidine-3-thiosemicarbazone coupled to L-proline 
and (S)-3-homoproline, respectively, and four new complexes with nickel(II), palladium(II) 
and copper(II) (Chart 1), their characterization by elemental analysis, spectroscopic methods, 
X-ray crystallography and antiproliferative activity in three human cancer cell lines (A549, 
CH1 and SW480) and in non-cancerous mouse fibroblasts (NIH/3T3). Clear-cut structure-
activity relationships were established and discussed.   
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Chart 1. Line drawings of L-proline and (S)-3-homoproline thiosemicarbazone conjugates 
H2L
1 and H2L
2, as well as of their nickel(II), palladium(II) and copper(II) complexes. We use 
for consistency the same abbreviation H2L
1 and H2L
2 for the overall charge-neutral ligand 
precursors and ligands, although the charge distribution in these species is clearly different. 
Underlined formula and numbers indicate compounds studied by X-ray crystallography. 
 
Experimental section 
 
Chemicals. All reagents were used as purchased from commercial suppliers. L-Proline was 
from Alfa Aesar. 4-Pyrrolidine-3-thiosemicarbazide20 was obtained in 60% yield by refluxing 
methyl hydrazinecarbodithioate 21  and pyrrolidine in water for 6 h. 3-Chloromethyl-2-
hydroxy-5-methylbenzaldehyde was synthesized by following a modified published 
procedure.22 Z-L-Proline23 and 3-homoproline24 were synthesized according to previously 
reported protocols. All utilized solvents were HPLC grade and used without further 
purification. 
 
Synthesis of Ligand Precursors 
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[1-(3-formyl-2-hydroxy-5-methylbenzyl)-(R/S)-pyrrolidine-2-yl]acetic acid methyl ester. 
To a solution of 3-chloromethyl-2-hydroxy-5-methylbenzaldehyde (0.94 g, 5.09 mmol) in 
THF (10 mL) was added a solution of methyl (R/S)-pyrrolidin-2-yl-acetate (0.79 g, 5.59 
mmol) in methylene chloride (5 mL) followed by a solution of triethylamine (1.09 mL, 7.64 
mmol) in THF (2 mL) and the reaction mixture was stirred at 60 °C for 10 h. Then THF (100 
mL) was added and the crystallized triethylammonium chloride was filtered off. The orange 
solution was concentrated under reduced pressure and purified by column chromatography by 
using a 1:1 mixture ethyl acetate/hexane as eluent (Rf = 0.14). The yellow oil was dried in 
vacuo. Yield: 1.18 g, 80%. 1H NMR (500.10 MHz, DMSO-d6): δ 10.24 (s, 1H, HC=O), 7.36 
(d, J = 2.0 Hz, 1H, Ar-H), 7.25 (d, J = 2.0 Hz, 1H, Ar-H), 4.16 (d, J = 14.1 Hz, 1H, Ar-CH2-
N), 3.60 (s, 3H, OCH3), 3.54 (d, J = 14.2 Hz, 1H, Ar-CH2-N), 2.98‒2.91 (m, 1H, Pyrr), 
2.91‒2.85 (m, 1H, Pyrr), 2.81‒2.74 (m, 1H, Pyrr), 2.45 (dd, J = 7.6 and 8.1 Hz, 2H, 
CH2COOMe), 2.33‒2.27 (m, 1H, Pyrr), 2.24 (s, 3H, CH3), 2.08‒2.00 (m, 1H, Pyrr), 
1.76‒1.67 (m, 3H, Pyrr), 1.61‒1.53 (m, 1H, Pyrr) ppm. 13C{1H} NMR (125.76 MHz, 
DMSO-d6): δ 191.78, 172.18, 159.25, 136.54, 128.19, 127.61, 125.57, 122.37, 61.01, 54.81, 
53.44, 51.80, 38.39, 30.53, 22.38, 20.35 ppm. ESI-MS in MeOH (positive): m/z 291.6 ([M + 
H]+). ESI-MS in MeOH (negative): m/z 289.3 ([M – H]−). 
 
H2L
1·2.5H2O. To a solution of 2-hydroxy-3-methyl-(S)-pyrrolidine-2-carboxylate-5-
methylbenzaldehyde (1.7 g, 6.5 mmol) in ethanol (30 mL) under stirring a solution of 4-N-
pyrrolidine-3-thiosemicarbazide (0.94 g, 6.5 mmol) in ethanol (10 mL) was added. The 
reaction mixture was refluxed at 85 °C for 1 h. Upon cooling to the room temperature the 
precipitate was filtered off, washed with cold ethanol (5 mL) and dried in vacuo overnight. 
Yield: 0.7 g, 25.2%. Anal. Calcd for C19H26N4O3S·2.5H2O (M 435.54 g mol
–1), %: C, 52.40; 
H, 7.17; N, 12.86; S, 7.36. Found, %: C, 52.29; H, 7.20; N, 12.70; S, 7.19. IR (ATR, selected 
bands, νmax): 3165, 3066, 2961, 2873, 1639, 1617, 1558, 1436, 1306, 1190, 961, 913, 757, 
619, 575 cm−1. UV–vis in MeOH, λ, nm (ε, M–1 cm–1): 390 (1220), 334 (11350), 300sh 
(14000), 288 (16265), 249sh (10910), 227 (19380).1H NMR (500.10 MHz, DMSO-d6): δ 
11.24 (s, 1H, NH), 8.47 (s, 1H, HC=N), 7.22 (s, 1H, Ar), 7.19 (s, 1H, Ar), 4.17 (d, J = 13.54 
Hz, 1H, CH2), 3.99 (d, J = 13.54 Hz, 1H, CH2), 3.66 (s, 4H, proline or pyrrolidine), 3.56–
3.52 (m, 2H, proline), 3.30–3.23 (m, 2H, proline), 2.85–2.77 (m, 1H, proline), 2.26 (s, 3H, 
CH3), 2.21–2.12 (m, 1H, proline), 2.01–1.90 (m, 4H, pyrrolidine), 1.90–1.82 (m, 1H, proline), 
1.75–1.65 (m, 1H, proline) ppm. ESI–MS in MeOH (positive): m/z 391 ([H2L
1 + H]+). Single 
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crystals of X-ray diffraction quality were obtained by slow diffusion of diethyl ether into 
ethanolic solution of H2L
1. 
   
H2L
2∙2H2O. To a solution of methyl[1-(3-formyl-2-hydroxy-5-methylbenzyl)-(R/S)-
pyrrolidin-2-yl]acetate (0.40 g, 1.37 mmol) in ethanol (30 mL) was added 4-N-pyrrolidine-3-
thiosemicarbazide (0.20 g, 1.37 mmol) in water (30 mL). The solution was stirred at 80 °C 
for 24 h and cooled to room temperature. The beige precipitate was filtered off, washed with 
diethyl ether (2 mL) and dried in vacuo. Yield: 0.24 g, 43%.; no m.p., decomposition without 
melting, onset at 170 °C. Anal. Calcd for C20H28N4O3S∙2H2O (M 440.56 g mol
–1), %: C, 
54.52; H, 7.32; N, 12.72; S, 7.28. Found, %: C, 54.36; H, 7.01; N, 12.33; S, 7.11. 1H NMR 
(500.10 MHz, DMSO-d6): δ 11.16 (br, 1H, N
2H), 8.47 (s, 1H, C15H), 7.12 (s, 1H, C4H + 
C6H), 3.97 (d, J = 13.7 Hz, 1H, C8H2), 3.58-3.72 (br, 4H, C
17H2 + C
20H2), 3.60 (d, J = 13.6 
Hz, 1H, C8H2), 3.04-2.97 (m, 1H, C
9H), 2.96-2.89 (m, 1H, C12H2), 2.44-2.33 (m, 3H, C
12H2 + 
C13H2), 2.26 (s, 3H, C
7H3), 2.10-2.00 (m, 1H, C
11H2), 1.98-1.87 (br, 4H, C
18H2 + C
19H2), 
1.76-1.63 (m, 2H, C10H2), 1.54-1.44 (m, 1H, C
11H2) ppm. 
13C{1H} NMR (125.76 MHz, 
DMSO-d6): δ 176.36, 173.45, 153.78, 146.35, 132.52, 129.54, 127.62, 124.91, 118.51, 61.17, 
53.24, 51.38, 37.75, 30.63, 22.44, 20.51 ppm. ESI-MS in MeOH (positive): m/z 405.38 
([M+H]+). Calcd for C20H29N4O3S: m/z 405.20. ESI-MS in MeOH (negative): m/z 403.19 
([M‒H]−). Calcd for C20H27N4O3S: m/z 403.18. IR (ATR, selected bands, νmax): 3364, 2965, 
2881, 1550, 1462, 1349, 1286, 915, 670, 607 cm−1. UV–vis in MeOH, λ, nm (ε, M–1 cm–1): 
335 (14327), 300 (15771), 288 (20648), 227 (22884). For atom labeling scheme and 
assignment of NMR resonances see Chart 1.   
 
Synthesis of Metal Complexes  
[Ni(H2L
1)Cl]Cl∙1.3H2O (1∙1.3H2O). To a solution of H2L
1∙2H2O (0.20 g, 0.47 mmol) in 
ethanol (20 mL) was added a solution of NiCl2∙6H2O (0.12 g, 0.50 mmol) in ethanol (5 mL) 
and the reaction mixture was stirred at room temperature for 2 h. The solvent was removed 
on a rotary evaporator under reduced pressure. The residue was dissolved in methanol (2 mL) 
and the product precipitated by addition of diethyl ether (20 mL) was filtered off, washed 
with diethyl ether (5 mL) and dried in air. Yield 0.21 g, 82.2%; no m.p., decomposition 
without melting, onset at 260 °C. Anal. Calcd for C19H26Cl2NiN4O3S∙1.3H2O (M 543.52 g 
mol1), %: C, 41.99; H, 5.30; N, 10.31; S, 5.90; Cl, 13.05. Found, %: C, 41.82; H, 5.20; N, 
10.49; S, 6.03; Cl, 13.30. IR (ATR, selected bands, νmax): 3204, 3108, 1733, 1598, 1548, 
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1496, 1450, 1360, 1215, 1201, 1180, 915, 887, 862, 706, 603 cm−1. UV–vis in MeOH, λ, nm 
(ε, M–1 cm–1): 865 (135), 770 (87), 620 (45), 398 (33100), 293 (38900), 259 (62300), 236 
(69600). ESI-MS in methanol (positive): m/z 447.26 [Ni(HL1)]+. Calcd for C19H25NiN4O3S 
m/z 447.10. X-ray diffraction quality single crystals were grown by slow diffusion of diethyl 
ether into the solution of the complex in methanol. Magnetic susceptibility measurements 
indicate its diamagnetism in the solid state. 
 
[Pd(H2L
1)Cl]Cl∙H2O (2∙H2O). To a solution of H2L
1∙2H2O (0.20 g, 0.47 mmol) in ethanol 
(20 mL) was added a solution of PdCl2 (0.09 g, 0.51 mmol) in ethanol (5 mL) and the 
reaction mixture was refluxed for 1 h. The solvent was removed on a rotary evaporator under 
reduced pressure. The residue was dissolved in methanol (2 mL) and the product precipitated 
by addition of diethyl ether (20 mL) was filtered off, washed with diethyl ether (5 mL) and 
dried in air. Yield 0.13 g, 47.2%. Anal. Calcd for C19H26Cl2PdN4O3S∙H2O (M 585.84 g 
mol1), %: C, 38.95; H, 4.82; N, 9.56; S, 5.47; Cl, 12.10. Found, %: C, 39.15; H, 4.43; N, 
9.56; S, 5.70; Cl, 12.40. IR (ATR, selected bands, νmax): 3200, 3101, 1733, 1544, 1495, 1449, 
1364, 1218, 1201, 1182, 1166, 863, 822, 600 cm−1. UV–vis in MeOH, λ, nm (ε, M–1 cm–1): 
412 (22340), 320 (31575), 244 (60220). 1H NMR (500.10 MHz, DMSO-d6): δ 9.99 (br, 1H, N
2H), 
8.31 (s, 1H, C14H), 7.27 (d, J = 2.0 Hz, 1H, C6H), 7.22 (d, J = 2.0 Hz, 1H, C4H), 4.55‒4.47 (m, 1H 
C9H), 4.42 (1H dd, J = 13.0, 5.0 Hz, C8Hb), 4.31 (C8Ha dd, J = 13.0, 5.0 Hz, 1H), 3.64‒3.55 (m, 
C12Hb 1H), 3.53‒3.47 (m, C16H 2H), 3.43‒3.34 (m, C12Ha 1H), 2.50‒2.41 (m, C10Hb 1H), 2.21 (s, 
C7H3, 3H,), 2.11‒1.98 (m, C
10Ha+C11Hb, 2H), 1.94‒1.86 (m, C11Ha, 1H) ppm. 13C NMR (126 MHz, ) 
δ 171.20, 170.35, 158.62, 146.79, 137.09, 135.24, 122.92, 120.03, 118.87, 66.01 (C9H), 62.69, 
55.95(C8H), 55.14(C12H), 51.24(C16H), 34.63, 28.42(C10H), 26.03(C17H), 22.86(C11H), 20.14(C7), 
14.29 ppm. ESI-MS in methanol (negative): m/z 530.93 [M‒HCl‒H]‒. Calcd for 
C19H24N4O3PdS m/z 531.03. Single crystals were grown from dimethyl sulfoxide at room 
temperature. 
 
[Cu(H2L
1)Cl]Cl∙0.7H2O (3∙0.7H2O). To a solution of H2L
1∙2H2O (0.20 g, 0.47 mmol) in 
ethanol (20 mL) was added a solution of CuCl2∙2H2O (0.09 g, 0.53 mmol) in ethanol (5 mL) 
and the reaction mixture was stirred at room temperature for 2 h. The solvent was removed 
on a rotary evaporator under reduced pressure. The residue was dissolved in methanol (2 mL) 
and the product precipitated by addition of diethyl ether (20 mL) was filtered off, washed 
with diethyl ether (5 mL) and dried in air. Yield 0.15 g, 59.4%. Anal. Calcd for 
C19H26Cl2CuN4O3S∙0.7H2O (M 537.56 g mol
1), %: C, 42.45; H, 5.14; N, 10.42; S, 5.97; Cl, 
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13.19. Found, %: C, 42.30; H, 4.97; N, 10.24; S, 6.25; Cl, 13.54. IR (ATR, selected bands, 
νmax): 3178, 3083, 1742, 1582, 1481, 1462, 1445, 1394, 1361, 1347, 1259, 1179, 911, 821, 
759, 700, 576 cm−1. UV–vis in MeOH, λ, nm (ε, M–1 cm–1): 635 (279), 403 (13347), 333sh 
(10050), 311sh (21397), 299 (29236), 267 (18430), 260sh (18410). ESI-MS in methanol 
(positive): m/z 452 [Cu(HL1)]+. 
 
[Cu(H2L
2)Cl]Cl∙H2O (4∙H2O). To a solution of H2L
2 (95 mg, 0.24 mmol) in methanol (10 
mL) was added CuCl2∙2H2O (44 mg, 0.26 mmol) in methanol (1 mL) and the reaction 
mixture was refluxed for 1 h. The green solution was concentrated to a volume of ca. 4 mL 
and allowed to stand at +4 °C for 6 h. The precipitate formed was filtered off, washed with 
diethyl ether (3 mL) and dried in vacuo. Yield: 70 mg, 55%; no m.p., decomposition without 
melting, onset at 220 °C. Anal. Calcd for C20H28Cl2CuN4O3S∙H2O (M 556.99 g mol
–1), %: C, 
43.13; H, 5.43; N, 10.06; S, 5.76. Found, %: C, 43.03; H, 5.12; N, 9.68; S, 5.55. ESI-MS in 
MeOH (positive): m/z 466.31 ([Cu(HL2)]+). Calcd for C20H27CuN4O3S: m/z 466.11. ESI-MS 
in MeOH (negative): m/z 464.10 ([Cu(L2‒H )]−), 500.05 ([Cu(L2)Cl]−). Calcd for 
C20H25CuN4O3S: m/z 464.09. Calcd for C20H26ClCuN4O3S: m/z 500.07. IR (ATR, selected 
bands, νmax): 3397, 2875, 2608, 1741, 1582, 1483, 1346, 1175, 910, 820, 759 cm
−1. UV–vis 
in MeOH, λ, nm (ε, M–1 cm–1): 616 (191) 403 (15457), 327 (14377), 297 (35476), 263 
(24855). Solvent-free sample is stable up to 210 °C. 
 
Crystallographic Structure Determination. X-ray diffraction measurements of H2L
1 and 1 
were performed on a Bruker D8 Venture, while those of 2 and 4 on Bruker X8 APEXII CCD 
and STOE diffractometers, all equipped with an Oxford Cryosystem cooler device. The 
single crystals of H2L
1, 1, 2 and 4 were positioned at 35, 35, 40 and 40 mm from the detector, 
and 1401, 1071, 636 and 2136 frames were measured, each for 20, 10, 20 and 38 s over 0.4, 
0.5, 1 and 1° scan width, respectively. The data were processed using SAINT software.25 
Crystal data, data collection parameters, and structure refinement details are given in Table 1. 
The structures were solved by direct methods and refined by full-matrix least-squares 
techniques. All non-hydrogen atoms were refined with anisotropic displacement parameters. 
H atoms were inserted in calculated positions and refined with a riding model. The 
pyrrolidine and proline rings in one one of the two crystallographically independent 
molecules of 1 were found to be disordered over two positions with s.o.f. 0.65:0.35 and 
0.75:0.25, respectively, without using any restraints implemented in SHELXL2014. SADI and 
EADP restraints were applied to resolve the static disorder observed in the co-crystallized 
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solvent molecules in H2L
1. The single crystal of 4 was weakly diffracting and the resolution 
of the collected X-ray data was estimated to be 1.02 Å. Nevertheless, the structure could be 
solved and electron density of the molecule is well-defined, allowing for the determination of 
the atomic connectivity and refinement with anisotropic temperature factors for all non-
hydrogen atoms. The following software programs and computer were used: structure 
solution, SHELXS-97; refinement, SHELXL-97;26 molecular diagrams, ORTEP-3;27 computer, 
Intel CoreDuo. CCDC1471829‒1471831 and 1492553. 
.
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Table 1. Crystal data and details of data collection for H2L
1, 1, 2 and 4.  
Compound H2L
1 1 2 4 
empirical formula  C20.25H31N4O4.25S C19H26Cl2N4O3NiS C19H26Cl2N4O3PdS C20H28Cl2CuN4O3S 
Fw 430.55 520.11 567.80 538.96 
space group C2 P21 P21 C2/c 
a [Å] 10.5018(4) 6.9292(2) 6.9628(5) 20.3880(16) 
b [Å] 24.7063(9) 18.4742(8) 18.5602(13) 14.1122(7) 
c [Å] 16.9193(7) 17.4103(7) 17.4498(12) 15.9901(12) 
 [°] 90.967(2) 101.171(2) 101.011(2) 100.503(6) 
V [Å3] 4389.3(3) 2186.49(14) 2213.5(3) 4523.6(5) 
Z 8 4 4 8 
 [Å] 0.71073 0.71073 0.71073 1.54186 
calcd [g cm
-3] 1.303 1.580 1.704 1.583 
crystal size [mm] 0.20  0.13  0.12 0.32  0.20  0.20 0.15  0.05  0.05  0.08  0.04  0.02 
T [K] 100(2) 130(2) 100(2) 100(2) 
 [mm-1] 0.182 1.257 1.203 4.658 
R1
[a] 0.0543 0.0341 0.0418 0.0555 
wR2
[b] 0.1493 0.0826 0.0899 0.1307 
Flack parameter 0.01(7) −0.02(3) −0.04(2)  
GOF[c] 1.029 1.023 1.023 0.942 
a R1 = ||Fo|  |Fc||/|Fo|. 
b wR2 = {[w(Fo
2  Fc
2)2]/[w(Fo
2)2]}1/2. c GOF = {[w(Fo
2  Fc
2)2]/(n  p)}1/2, where n is the number of reflections 
and p is the total number of parameters refined.  
 12
One-dimensional 1H and 13C NMR and two-dimensional 1H−1H COSY and 1H−13C HMBC 
NMR spectra were recorded on two Bruker Avance III spectrometers at 500.32 or 500.10 
(1H) and 125.82 or 125.76 (13C) MHz, respectively, at room temperature, and using standard 
pulse programs. 1H and 13C shifts are quoted relative to the solvent residual signals. 
Electrospray ionization mass spectrometry (ESI-MS) was carried out with a Bruker Esquire 
3000 instrument and the samples were dissolved in methanol. Elemental analyses were 
performed at the Microanalytical Laboratory of the University of Vienna with a Perkin Elmer 
2400 CHN Elemental Analyzer (Perkin Elmer, Waltham, MA). IR spectra were measured on 
a Bruker Vertex 70 Fourier transform IR spectrometer by using the ATR technique. UV‒vis 
absorption spectra were recorded on JASCO V770 spectrophotometer, while CD spectra on 
JASCO J1500 spectrometer. The spectra were measured at room temperature in a cuvette 
with 10 mm path length.  
 
Antiproliferative activity. CH1 cells (human ovarian carcinoma) were a generous gift from 
Lloyd R. Kelland, CRC Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, 
UK. SW480 (human adenocarcinoma of the colon) and A549 (human nonsmall cell lung 
cancer) cells were kindly provided by Brigitte Marian (Institute of Cancer Research, 
Department of Medicine I, Medical University of Vienna, Austria). NIH/3T3 (ATCC CRL-
1658) mouse embryonic fibroblasts were cultured according to the ATCC (American Type 
Culture Collection) protocol. All cell culture media and reagents were purchased from 
Sigma-Aldrich Austria and plastic ware from Starlab Germany. CH1, SW480, A549 cells 
were grown in 75 cm² culture flasks as adherent monolayer cultures in Minimum Essential 
Medium (MEM) supplemented with 10% heat-inactivated fetal calf serum, 1 mM sodium 
pyruvate, 4 mM L-glutamine and 1% non-essential amino acids (from 100x ready-to-use 
stock). NIH/3T3 cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) 
supplemented with 10% of bovine calf serum. Cultures were maintained at 37 °C in 
humidified atmosphere containing 95% air and 5% CO2. 
 
Cytotoxic effects of the test compounds were determined by means of a colorimetric 
microculture assay [MTT assay; MTT = 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide]. Cisplatin (Teva) was used as a positive control. Cells were harvested 
from culture flasks by trypsinization and seeded by using a pipetting system (Biotek 
Precision XS Microplate Sample Processor) in densities of 3 × 103 (A549), 1 × 103 (CH1) 
and 2 × 103 (SW480) in 100 μL/well aliquots in 96-well microculture plates. For 24 h, cells 
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were allowed to settle and resume proliferation. Test compounds were then dissolved in 
DMSO, diluted in complete culture medium and added to the plates where the final DMSO 
content did not exceed 0.5%. After 96 h of drug exposure, the medium was replaced with 100 
μL/well of a 1:7 MTT/RPMI 1640 mixture (MTT solution, 5 mg/mL of MTT reagent in 
phosphate-buffered saline; RPMI 1640 medium, supplemented with 10% heat-inactivated 
fetal bovine serum and 4 mM L-glutamine), and plates were incubated for further 4 h at 37 °C. 
Subsequently, the solution was removed from all wells, and the formazan crystals formed by 
viable cells were dissolved in 150 μL of DMSO per well. Optical densities at 550 nm were 
measured with a microplate reader (Biotek ELx808) by using a reference wavelength of 690 
nm to correct for unspecific absorption. The quantity of viable cells was expressed relative to 
untreated controls, and 50% inhibitory concentrations (IC50) were calculated from 
concentration-effect curves by interpolation. Evaluation is based on means from three 
independent experiments. A slightly modified procedure was used to test the antiproliferative 
effect in NIH/3T3 mouse embryonal fibroblast cells, which is provided in the SI. 
 
Mechanisms of cell death: assay for apoptosis induction. The assay was carried out using 
Annexin V-FITC Apoptosis Detection Kit Cat. No. PF 032 from Calbiochem according to the 
manufacturer's instructions. The concentration of the A549 cell suspension was adjusted to 
approximately 0.5×106 cells/mL in MEM and the cell suspension was distributed into 1 mL 
aliquots to a 24-well plate, then incubated overnight at 37 °C, 5% CO2. On the following day, 
the medium was removed and replaced by 1 mL MEM containing the compounds except the 
control samples. A549 cells were incubated in the presence of the compounds at 20 M in the 
24-well plate for 3 h at 37°C, 12H-benzo[]phenothiazine (M627)28 and cisplatin (Teva) at 
20 M were used as positive controls. After the incubation period the samples were washed 
with PBS and fresh MEM medium was added to the samples. The cells were incubated 
overnight at 37 °C, 5% CO2. On the following day, 200 L 0.25% Trypsin (Trypsin-Versen) 
was added to the samples until cells appeared detached followed by the addition of 400 L of 
MEM supplemented with 10% bovine serum. The cells were collected to Eppendorf tubes 
and centrifuged at 2000 g for 2 min. The harvested cells were resuspended in fresh serum free 
MEM culture medium. After this step, the apoptosis assay was carried out according to the 
rapid protocol of the kit. The fluorescence was analyzed immediately using a ParTec CyFlow 
flow cytometer (Partec GmbH, Münster, Germany). 
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Results and Discussion 
Synthesis and Characterization of Ligands and Metal Complexes. The chiral 2-hydroxy-
3-methyl-(S)-pyrrolidine-2-carboxylate-5-methylbenzaldehyde 4-N-pyrrolidine-3-
thiosemicarbazone has been prepared in three steps as described recently for unsubstituted at 
terminal nitrogen atom of the thiosemicarbazide moiety derivative.19 First 3-chloromethyl-2-
hydroxy-5-methylbenzaldehyde22 was allowed to react with L-proline methyl ester 
hydrochloride in the presence of triethylamine with formation of the desired conjugate. 
Condensation reaction of this latter compound with 4-N-pyrrolidine-3-thiosemicarbazide20 
followed by hydrolysis of the methyl ester group afforded the corresponding TSC with 
coupled via a methylene group L-Pro moiety (H2L
1). The formation of desired species has 
been confirmed by 1H and 13C NMR measurements, as well as by ESI mass spectra. The mass 
spectrum recorded in positive ion mode showed peaks at m/z 391 due to [M+H]+ ion. 
Aqueous solution of H2L
1 at neutral pH is optically active. The second optically active ligand 
H2L
2 was obtained similarly by using the (R/S)-β3-homoproline methyl ester instead of the L-
proline methyl ester hydrochloride. The latter was prepared via a four-step procedure by 
exploring the Arndt-Eistert reaction as a common method of homologization of an -amino 
acid into -amino acid (e.g., proline to 3-homoproline) as shown in Scheme S1.24 Briefly, in 
the first step the secondary amine in L-proline was protected by reaction with benzyl 
chloroformate in aqueous KOH solution. Then the N-protected L-proline was converted into 
the acyl halide by treating with excess oxalylchloride in dichloromethane followed by 
methylation with TMS-diazomethane and formation of the -diazotylketone. This latter 
conversion called Wolff rearrangement is the key step involving the insertion of CH2-group.
29 
The -diazotylketone was further rearranged in dry methanol in the presence of silver 
benzoate and triethylamine. Finally the amino group was deprotected with H2 in the presence 
of 10% PdC in dry methanol. The synthesis can be performed in large scale with 51% overall 
yield of β3-homoproline methyl ester. The reaction of β3-homoproline methyl ester with 3-
chloromethyl-2-hydroxy-5-methylbenzaldehyde in THF/CH2Cl2 afforded [1-(3-formyl-2-
hydroxy-5-methylbenzyl)-(R/S)-pyrrolidin-2-yl]acetic acid methyl ester purified by column 
chromatography giving an orange oil in 80% yield. Condensation of this product with 4-N-
pyrrolidine-3-thiosemicarbazide accompanied by hydrolysis of the ester group resulted in 
H2L
2 in 43% yield. The formation of the desired ligand precursor was confirmed by ESI mass 
spectrometry which showed the presence of a peak with m/z 405, attributed to [M+H]+ ion, as 
well as by 1H and 13C NMR spectra. 
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By reaction of H2L
1 with NiCl2∙6H2O in ethanol at room temperature the red complex 
[Ni(H2L
1)Cl]Cl∙1.3H2O was synthesized in 82% yield. Similarly starting from PdCl2 and 
CuCl2∙2H2O the complexes [Pd(H2L
1)Cl]Cl∙H2O and [Cu(H2L
1)Cl]Cl∙0.7H2O were isolated 
in 47 and 59% yield, respectively. ESI mass spectra of 1 and 3 measured in the positive ion 
mode exhibit a strong peak at m/z 447.26 and m/z 452, which can be assigned to [Ni(HL1)]+ 
and [Pd(HL1)]+, respectively, while the negative ion mass spectrum of 2 contains a strong 
signal at m/z 530.93 due to [Pd(L1)Cl]‒. By reaction of a methanolic solution of CuCl2∙2H2O 
with H2L
2 the complex [Cu(H2L
2)Cl]Cl∙H2O was obtained in 55% yield. ESI mass spectrum, 
recorded in positive ion mode, showed the presence of a strong peak at m/z 466.31 attributed 
to [CuII(HL2)]+, while in negative ion mode peaks with m/z 464.10 and 500.05 due to 
[CuII(L2−H)]− and [CuII(L2)Cl]− respectively, were observed in agreement with the proposed 
structure. 
 
X-ray crystallography. Figure 1 shows the structure of the chiral ligand precursor H2L
1 with 
selected bond distances and angles quoted in the legend. The compound crystallizes in the 
monoclinic space group C2 with two crystallographically independent molecules in the 
asymmetric unit. The conformation adopted by H2L
1 is very close to that of the ligand in 
complexes 1 and 2 (vide infra). The prolinic moiety is in the zwitterionic form, what makes 
atom N4a in addition to C14a chiral. A strong intramolecular hydrogen bonding O1a‒H∙∙∙N1a 
with O1a∙∙∙N1a 2.595(4) Å and O1a‒H∙∙∙N1a 143.4° is evident in the structure of H2L
1.  The 
atoms N2a and N4a act as proton donors to O3ai(‒x + 1, y, ‒z + 1) and O2bi(‒x + 1, y, ‒z + 1), 
respectively, forming hydrogen bonds N2a‒H∙∙∙O3ai and N4a‒H∙∙∙O2bi with N2a∙∙∙O3ai 
2.736(5) Å, N2a‒H∙∙∙O3ai 155.5° and N4a∙∙∙O2bi 2.857(5) Å, N2a‒H∙∙∙O3ai 136.7°.   
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Figure 1. ORTEP view of H2L
1 with thermal displacement parameters drawn at the 50% 
probability level. Selected bond distances (Å) and torsion angles (deg): C1a‒O1a 1.352(4), 
N1a‒N2a 1.367(3), N2a‒C8a 1.368(4), C8a‒S1a 1.694(3), C8a‒N3a 1.335(4); 
ΘC1a‒C2a‒C10a‒N4a ‒91.6(3); ΘC10a‒N4a‒C14a‒C15a ‒100.8(3). 
 
The results of X-ray diffraction studies of 1, 2 and 4 are shown in Figures 2 and 3. The 
compounds 1 and 2 are isostructural and crystallized in the noncentrosymmetric monoclinic 
space group P21 as pure enantiomers, as also confirmed by the Flack parameters quoted in 
Table 1, with two chiral atoms of the same configuration (vide infra). Complex 4 crystallized 
in the centrosymmetric monoclinic space group C2/c. The asymmetric unit in 1 and 2 consists 
of two crystallographcally independent cations [M(H2L
1)Cl]+ (M = Ni, Pd) and two chloride 
counterions, where H2L
1 is the charge-neutral proline-thiosemicarbazone hybrid, while that of 
4 of one complex [Cu(H2L
2)Cl2]. The ligands H2L
1 in 1 and 2 and, H2L
2 in 4 act as tridentate 
binding to the metal(II) via phenolate oxygen atom O1, nitrogen atom N1 and thione sulfur 
S1 as shown in Figures 2 and 3 for one of the two crystallographically independent cations 
[Ni(H2L
1)Cl]+, [Pd(H2L
1)Cl]+ and complex [Cu(H2L
2)Cl2]. The ligands are deprotonated at 
O1, but protonated at N4, so that the overall protonation level does not change. Protonation at 
N4 makes this atom chiral (S configuration) in 1 and 2. The second chiral centre C14 has the 
same S configuration. According to the literature the nitrogen atom of L-prolinate ligand or 
moiety upon coordination to metal ion or protonation in most cases adopts the same 
configuration as the asymmetric carbon atom,30 although cases when the two atoms adopt 
opposite configurations are also known. 31  The coordination geometry of nickel(II) and 
palladium(II) is square-planar. The fourth coordination place is occupied by a chlorido ligand.  
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The overall positive charge of the complex cation is counterbalanced by another chloride ion.  
The Pd−O, Pd−N, PdCl and Pd−S bond lengths in 2 are well-comparable to those found in 
complex [Pd(HSal4Et)Cl]∙H2O, where H2Sal4Et = 2-hydroxybenzaldehyde 4-N-
ethylthiosemicarbazone, at 2.019(2), 1.965(2), 2.3078(8) and 2.2456(9) Å, respectively.32 The 
protonated atom N4a in cation A acts as proton donor in bifurcated hydrogen bonding 
interaction to O2a and Cl2i (x − 1, y, z − 1), while N4b in cation B to O1B and O2B as shown 
in Figure S1. In addition, strong hydrogen bonding interactions N2a−H∙∙∙Cl2a [N2a∙∙∙Cl2a 
3.157(6) Å, N2a−H∙∙∙Cl2a 160.2°], N2b−H∙∙∙Cl2bii (−x + 1, y − 0.5, −z + 1) [N2b∙∙∙Cl2bii 
3.162(0) Å, N2b−H∙∙∙Cl2bii 156.5°] and O3b−H∙∙∙Cl2aii (−x + 1, y + 0.5, −z + 1) [O3b∙∙∙Cl2aii 
2.926(0) Å, O3b−H∙∙∙Cl2aii 170.4°] are evident in the crystal structure of 2. Closely similar 
hydrogen bonding interactions for 1 are quoted in Table S1. 
 
Figure 2. ORTEP view of one of the two crystallographically independent complex cations 
in the asymmetric unit of [Ni(H2L
1)Cl]Cl (left) and [Pd(H2L
1)Cl]Cl (right) with atom labeling 
schemes; thermal ellipsoids were drawn at 50% probability level. Selected bond distances (Å) 
and bond angles (deg) [Ni(H2L
1)Cl]Cl: Ni1a−Cl1a 2.184(3), Ni1a−O1a 1.858(7), Ni1a−N1a 
1.848(10), Ni1a−S1a 2.147(3), C1a−O1a 1.300(14), N1a−N2a 1.392(12), N2a−C8a 
1.340(15), C8a−S1a 1.708(13), C8a−N3a 1.311(15); O1a−Ni1a−N1a 93.6(4), N1a−Ni1a−S1a 
88.8(3).  Selected bond distances (Å) and bond angles (deg) [Pd(H2L
1)Cl]Cl: Pd1a−Cl1a 
2.3049(12), Pd1a−O1a 2.016(3), Pd1a−N1a 1.976(4), Pd1a−S1a 2.2470(11), C1a−O1a 
1.320(5), N1a−N2a 1.382(5), N2a−C8a 1.350(5), C8a−S1a 1.722(5), C8a−N3a 1.318(5); 
O1a−Pd1a−N1a 92.39(14), N1a−Pd1a−S1a 86.53(11).    
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A feature of note is the presence of short intermolecular contacts Ni∙∙∙S and Pd∙∙∙S between 
neighbouring complex cations of ca. 3.69 ‒ 3.70 and 3.59  3.60 Å, respectively, as shown in 
Figures S2 and S3. The interplanar separation between aromatic ring of the interacting 
species is ca. 3.25 and 3.16 Å, in 1 and 2, respectively. Formation of short contacts of this 
type is not characteristic for the complex [Pd(HSal4Et)Cl]∙H2O mentioned previously.    
 
Figure 3. ORTEP view of 4 with atom labeling schemes; thermal ellipsoids were drawn at 
50% probability level. Selected bond distances (Å) and bond angles (deg): Cu−Cl1 2.294(2), 
Cu−Cl2 2.732(3), Cu−N1 2.001(8), Cu‒O1 1.916(6), Cu−S 2.262(3), C1−O1 1.339(11), 
N1−N2 1.373(10), N2−C8 1.376(11), C8−S 1.702(10), C8−N3 1.320(12); O1−Cu−N1 
90.3(3), N1−Cu−S 86.1(2).   
 
The coordination polyhedron of copper(II) in 4 is best described as a square-pyramid ( = 
0.15).33 The tridentate ligand H2L
2 and one chloride occupy the basal plane, while second 
chlorido ligand the apical position. Comparison of the bond lengths Cu‒Cl1 and Cu‒Cl2 (see 
legend to Figure 3) indicates markedly weaker binding of the apical chlorido ligand to 
copper(II). The protonated atom N4 acts as proton donor in intramolecular bifurcated 
hydrogen bonding interaction to O1 and Cl2 [N4∙∙∙O1 2.624(10) Å, N4‒H∙∙∙O1 132.5°; 
N4∙∙∙Cl1 3.684(8) Å, N4‒H∙∙∙Cl1 149.0°]. In addition, strong intermolecular hydrogen 
bonding interactions N2−H∙∙∙Cl2ii (−x + 1, −y + 1, −z) [N2∙∙∙Cl2ii 3.197(8) Å, N2−H∙∙∙Cl2ii 
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156.6°] and O3−H∙∙∙Cl2i (x, −y + 1, z + 0.5) [O3∙∙∙Cl2i 2.925(7) Å, O3−H∙∙∙Cl2i 167.5°] are 
evident in the crystal structure of 4.     
 
NMR spectroscopy. The 1H NMR spectra of 2 and H2L
1 have been analyzed. The 2D 
homonuclear COSY 1H‒1H and heteronuclear HMBC 1H‒13C correlations were applied to 
assign the NMR signals (see Figure S4). The NMR spectra of H2L
1 are consistent with X-ray 
diffraction structure. We note here the particular splitting of protons of the methylene group 
which connects the aromatic and proline rings. The two protons C8Ha and C
8Hb are 
magnetically inequivalent due to their different spatial orientation with respect to the bond 
C8H2‒N
4C9C12. The simulation of the 1H NMR spectra (Figure 4) resulted in the geminal 
2JC8Ha-C8Hb constant of 13 Hz and chemical shifts δC8Ha = 4.177 and δC8Hb = 4.005 ppm. The 
proton in α position (C9H δC9H = 3.554 ppm) of the proline ring is split due to its vicinal 
proton-proton interaction with the two protons C10H2. The approximate dihedral angle for the 
adopted in this case conformation (Figure 4, right part) can be calculated by using the 
Karplus equation:34,35 
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Figure 4. Experimental (500 MHz) and simulated 1H NMR spectra of 2 (left) and H2L
1 
(right). 
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The conformation of the proline ring in H2L
1 is consistent with previously reported data.36,37 
As can be seen from Figure 3, the C8H2 group in 2 has different splitting pattern and chemical 
shift in comparison with H2L
1. A similar change in chemical shift is observed for C9H. The 
downfield shift of proton resonances of the proline ring in 2 can be related to double 
protonation of the proline group (amine nitrogen and carboxylato group) in the complex in 
comparison to single protonation in the zwitterionic form of the ligand. The single crystal X-
ray analysis shows that the proline nitrogen (N4) is protonated both in H2L
1 and in 2. In the 
case of complex 2 additional protonation of the ligand at O3a is also proved by X-ray 
analysis. The protonation state of N4 is also preserved in solution (DMSO), in accord with the 
additional splitting of two protons of C8H2 group. The modification in the splitting pattern of 
C8H2 signals can be associated with the change of spatial orientation of C
8H2 group after 
coordination. According to the simulation of the NMR spectra the best fit between theoretical 
and experimental spectra indicates the same magnitude of vicinal coupling constant between 
the protons C8Ha and HN
4 and C8Hb and HN
4 and corresponds to the dihedral angle of 40° 
(3JC8H-HN4 = 5.0 Hz) (Figure 3). This value indicates an average position between free 
rotations around C8H2‒N
4C9C12 single bond on the time scale of NMR spectroscopy. The 
protonation also affects the splitting of the α proton (C9H), and all 1H NMR resonances are 
upfield shifted (δC8Ha = 4.419, δC8Hb = 4.307 and δC9H = 4.509 ppm). The HN
4 signal appears 
in the 1H NMR spectra at 9.97 ppm as broad signal (13.0 Hz) as a consequence of splitting 
and chemical exchange in solution. The correlations between HN4 with C8H2 and C
9H were 
confirmed by the presence of cross peaks in COSY 1H‒1H spectra (Figure S5). The geminal 
2JHa-Hb constant is of the same magnitude of 13.0 Hz. 
 
Dissolution of red solid of 1 in methanol resulted in formation of a green solution suggesting 
a change in coordination geometry of Ni(II). 1H NMR spectrum of 1 showed broad lines, 
which indicated the presence of paramagnetic species in solution. We have determined the 
effective magnetic moment of 1 in CD3OD (1.58  10
‒2 M) at 298 K by using the NMR 
method of Evans.38 The value amounts to 3.26 B.M., which is typical for octahedral nickel(II) 
complexes with d8 electronic configuration.39 The CD spectrum of a methanolic solution of 1 
(Figure 4, green trace) indicates the presence of asymmetric centers in the molecule. The CD 
signals are correlated to the absorption bands for the ligand precursor and show the absence 
of CD signals in the visible region. The absence of CD signals in the visible region of the 
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spectrum indicates that the proline moiety with its two asymmetric centers is not bound to the 
nickel(II) in solution. 
 
The electronic absorption spectrum of 1 in methanol in the visible and NIR regions shows 
three bands with max at 865 (11560 cm
‒1), 770 (12987 cm‒1) and 620 (16129 cm‒1) nm 
(Figure 5) which can be attributed to 3A2g  
3T2g(F), 
3A2g  
1Eg(D) and 
3A2g  
3T1g(F) 
transitions of Ni(II) in octahedral environment, respectively.40 Spin-allowed transitions are 
known to give broad absorption bands, while spin-forbidden transitions are usually sharp.41 
For nickel(II) (d8) in octahedral environment 3A2g is the ground term and the spin allowed 
transition 3A2g  
3T2g(F) is equal to the value of the crystal field splitting (10Dq).
42 The 
value (11560 cm-1) is consistent with those reported for octahedral nickel(II) complexes.43 
The third characteristic transition 3A2g  
3T1g(P) is expected in the range of 19000 ‒ 27000 
cm‒1, which is obscured by strong intraligand absorption bands. 
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Figure 5. CD (green trace) and UV-vis absorption spectra (blue trace) of 1 in methanol. 
 
Stability in aqueous solution. Quite recently we reported on complexation reactions of 
copper(II) with L-Pro-STSC in 30% (w/w) DMSO/H2O.
19 Several determined 
thermodynamic cumulative stability constants (log ([CuLH]) = 21.58(3), log ([CuL]) = 
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17.54(3) and log ([CuLH‒1]) = 6.97(4)) along with the computed pM (= ‒log[M]) value of 
13.4 (pH 7.4, cCu = 1 M; cL/cCu = 10) undoubtedly indicate significantly high stability of 
copper(II) complexes, which are closely related to those studied in this work (3 and 4). In 
addition, we monitored the behavior of 4 in aqueous solution with 1% DMSO by UV‒vis 
spectroscopy. The data (Figure S7) indicates that the complex remains intact over 24 h in 
solution.    
 
Cytotoxicity and mechanism of cell death. The antiproliferative activity of two organic 
hybrids H2L
1 and H2L
2 and four metal complexes 1−4 was investigated in the human cancer 
cell lines A549 (nonsmall cell lung carcinoma), CH1 (ovarian carcinoma) and SW480 (colon 
carcinoma) by means of the colorimetric MTT assay.  Generally, CH1 cells are more 
sensitive to the compounds investigated in this work, giving up to 5 times lower IC50 values 
than SW480 cells, while A549 cells are less sensitive giving up to 9 times higher IC50 values 
than SW480 cells. The ligand precursors H2L
1 and H2L
2 and complexes 1−4 show different 
cytotoxic potencies, with IC50 values ranging from 0.9 to 308 µM (Table 2). The following 
structure-activity relationships are of note: (i) impact of metal coordination as compared to 
the uncomplexed ligand precursors; (ii) negligible role of square-planar coordination 
geometry of metal complexes in underlying mechanism of their cytotoxicity; (iii) the impact 
of substitution at terminal nitrogen atom of thiosemicarbazide moiety and (iv) the effect of 
increasing the structural flexibility of amino acid moiety by insertion of methylene group 
between the pyrrolidine ring and carboxylic group (proline vs homoproline). The impact of 
the central metal ion identity on the activity of ligands H2L
1 and H2L
2 are pronounced, and 
notably they are divergent for H2L
1. Complexation of H2L
1 to nickel(II) and palladium(II) 
weakens markedly the antiproliferative activity in all three cell lines, in line with other 
reported data.44 The IC50 values of the nickel(II) complex 1 indicate roughly 10- (A549), 7.5- 
(CH1) and 2.7-fold (SW480) reduction and those of palladium(II) complex 2 a 13- (A549), 
23- (CH1) and 26-fold (SW480) drop of cytotoxicity when compared to that of H2L
1. In 
contrast, complexation of H2L
1 to copper(II) results in a 9.5- (A549), 3- (CH1) and 10-fold 
(SW480) increase of cytotoxicity based on IC50 values. Similarly, complexation of H2L
2 to 
copper(II) gives a 3.8- (A549), 3.4- (CH1) and 8.6-fold (SW480) increase of cytotoxicity. 
Since complexes 1−3 are square-planar based on X-ray diffraction data of 1 and 2, and X-ray 
crystallography data on previously studied copper(II) complex [Cu(D-Pro-STSC)Cl]Cl,19 
which is closely related to 3 and 4, we can conclude that the role of coordination geometry in 
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the underlying mechanism of cytotoxicity seems to be marginal, if any, if we compare the 
IC50 values of 1−3 with that of H2L
1. This conclusion remains valid, if we exclude 1 from the 
series due to the change in coordination geometry in solution to octahedral. Substitution at 
the terminal nitrogen atom of thiosemicarbazide moiety, namely pyrrolidine vs NH2 has a 
marked effect on cytotoxicity as well, which can be compared with that of metal coordination. 
A 23- (CH1) and more than 10-fold (SW480) decrease of IC50 values is achieved via this 
substitution for metal-free compounds, and a 5 to 5.5-fold decrease for the same structural 
modification in copper(II) complexes.19 Insertion of a CH2 group between the pyrrolidine 
ring and COOH group of amino acid moiety reduces markedly the antiproliferative activity of 
both ligand precursor and its copper(II) complex. Based on IC50 values a maximal 8-fold drop 
of cytotoxicity was observed on going from 3 to 4. Antiproliferative activity of complex 3 is 
slightly lower, but comparable to the clinical drug cisplatin. Compounds found to be active 
(H2L
1, H2L
2, complexes 3 and 4) in human cancer cells were tested for their antiproliferative 
activity in non-cancerous mouse embryonal fibroblast (NIH/3T3) cell lines as well. These 
compounds showed no selectivity as their activity in the normal cells is comparable to that 
obtained for the tumor cells.  
Table 2. Inhibition of cancer cell growth  of ligand precursors and metal complexes in human 
non-small cell lung (A549) carcinoma cell lines, ovarian (CH1),  colon (SW480) and 
NIH/3T3 mouse embryonal fibroblast cells; 50% inhibitory concentrations (means ± standard 
deviations), obtained by the MTT assay (exposure time 96 h). 
IC50 value ± SD 
 A549 CH1 SW480 NIH/3T3a 
H2L
1 22.9 ± 3.0 2.7 ± 0.2 9.8 ± 1.0 21.0 ± 1.0 
H2L
2 72 ± 5 6.7 ± 0.1 32 ± 2 34.7 ± 0.2 
1 226.2 ± 17.1 20.3 ± 4.5 26.0 ± 4.3 ‒ 
2 307.9 ± 6.5 62.0 ± 3.3 252.1 ± 19.6 ‒ 
3 2.4 ± 0.3 0.90 ± 0.08 0.99 ± 0.09 3.4 ± 0.3 
4 19 ± 3 2.0 ± 0.1 3.7 ± 0.1 13.8 ± 0.8 
CuCl2∙2H2O
b ‒ 43 ± 3 > 160 ‒ 
cisplatin 1.3± 0.4c 0.16± 0.03c 3.5± 0.3c 2.3± 0.4 
a Applied protocol described in the SI. b Taken from ref.44.c Taken from ref.45 
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The mechanism of cytotoxicity induced by complexes (H2L
1, H2L
2, complexes 3 and 4) was 
assessed by analysis of A549 cells stained for Annexin-V and and propidium iodide (PI) 
using flow cytometry. Compounds M627 and cisplatin were used as positive controls. 
Apoptosis is a fundamental mode of cell death which performs a regulatory function during 
normal development, in tissue homeostasis, and in some disease processes. In normal viable 
cells phosphatidyl serine (PS) is located on the cytoplasmic surface of the cell membrane. 
Upon induction of apoptosis, rapid alterations in the organisation of phospholipids in most 
cell types occurs leading to exposure of PS on the cell surface. In this assay a fluorescein 
isothiocyanate (FITC) conjugate of Annexin-V (a Ca-dependent phospholipid-binding protein 
with high affinity for PS) is used allowing detection of apoptosis. Since membrane 
permeabilisation is observed in necrosis, necrotic cells will also bind Annexin-V‒FITC. PI is 
used to distinguish between viable, early apoptotic and necrotic or late apoptotic cells. 
Necrotic cells bind Annexin-V‒FITC and stain with PI, while PI is excluded from viable 
(FITC negative) and early apoptotic (FITC positive) cells. In the absence of phagocytosis 
final stages of apoptosis involve necrotic-like disintegration of the total cell, thus cells in late 
apoptosis will be labeled with both FITC and PI. Fluorescence of PI (FL3) is plotted versus 
Annexin-V fluorescence (FL1) as shown in Figure 6 for the positive controls and complex 4. 
The early apoptosis in percentage were compared for the tested compounds (Figure S8).  
Elevated early apoptosis was observed for one of the studied ligand precursors (H2L
2) and 
complexes 3 and 4 as well as for cisplatin and M627 compared with the DMSO control. 
According to these data the studied compounds can be considered as moderate apoptosis 
inducers. The percentage of the late apoptosis and necrosis gated events was found to be 
significantly higher for the metal free precursors (H2L
1: 51.9%, H2L
2: 68.7% vs complex 3: 
24.7% and 4: 30.1%) at the applied concentration (20 M).    
 
M627 cisplatin complex 4
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Figure 6. Quantification of apoptosis in cells treated with complex 4 and M627, cisplatin (as 
positive controls) using the Annexin-V/PI double staining assay. A549 cells were treated with 
20 µM of compounds. The dual parametric dot plots combining Annexin-V (FL1) and PI 
(FL3) ﬂuorescence show the viable cell population in the lower left quadrant Annexin-V-/PI- 
(Q4), the early apoptotic cells in the lower right quadrant Annexin-V+/PI- (Q3), and the late 
apoptotic cells in the upper right quadrant Annexin-V+/PI+ (Q2). (Number of cells counted: 
19914 (M627), 9823 (cisplatin) 17166 (4).) 
 
Conclusions 
Two homologous optically active L-proline- and 3-homoproline-thiosemicarbazone 
conjugates H2L
1 and H2L
2 were synthesized via multistep procedures. Substitution of the 
terminal amino group by pyrrolidine should presumably increase the lipophilicity, while 
insertion of one CH2 group between the pyrrolidine moiety and COOH group of the amino 
acid enhanced the structural flexibility of the potential ligand. Both ligands were found to 
form square-planar complexes [Ni(H2L
1)Cl]Cl∙1.3H2O (1∙1.3H2O), [Pd(H2L
1)Cl]Cl∙H2O 
(2∙H2O),  [Cu(H2L
1)Cl]Cl∙0.7H2O (3∙0.7H2O) and [Cu(H2L
2)Cl]Cl∙H2O (4∙H2O) by reactions 
of the ligands with the corresponding metal salts in ethanol or methanol. The two 
homologous ligand precursors and four metal complexes proved to be suitable for performing 
antiproliferative activity assays and establishment of notable and clear-cut structure-
cytotoxicity relationships for three human cancer cell lines (A549, CH1 and SW480). The 
metal ions exert marked effects in a divergent manner: copper(II) modulates  the cytotoxic 
potency of H2L
1 and H2L
2 in a beneficial way, whereas coordination to nickel(II) and 
palladium(II) impairs the antiproliferative activity of H2L
1. The cytotoxicity of H2L
1 and 
metal complexes 1−3 decreases in all three cell lines in the following rank order: 3 > H2L
1 > 
1 > 2. Complex 3 exhibits the highest biological activity in all three cell lines with IC50 values 
of 2.4, 0.9 and 1.0 µM in A549, CH1 and SW480 cells, respectively. On the other hand 
compounds H2L
1, H2L
2, complexes 3 and 4 exhibited no tumor selectivity to cancerous cell 
lines over normal cells. The flow cytometry analysis of A549 cells stained for Annexin-V/PI 
showed induced early apoptosis in the case H2L
2 and complexes 3 and 4. The role of square-
planar geometry in 1−3 (or more strictly in 2 and 3) in the underlying mechanism of 
cytotoxicity seems to be negligible, while structural modifications at the terminal amino 
group of thiosemicarbazide and amino acid moiety have a significant impact on the 
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antiproliferative activity of both ligand precursors and copper(II) complexes. Substitution of 
the terminal NH2 group of thiosemicarbazide moiety by pyrrolidinyl one resulted in 23- (in 
CH1 cells) and > 10-fold enhancement of cytotoxicity of metal-free compounds, and 5 to 5.5-
fold increase for corresponding copper(II) complexes. In contrast, homologisation via 
insertion of a CH2 group between pyrrolidine ring and carboxylate moiety of the amino acid, 
reduced markedly the cytotoxicity of the ligand and its copper(II) complex. The SARs found 
will be explored further for the development of effective anticancer agents in the discovered 
series of thiosemicarbazone-proline hybrids. 
 
Supporting Information 
Synthesis pathway to H2L
2 (Scheme S1), ORTEP view of another crystallographically 
independent cation of 2 showing intermolecular hydrogen bonding interactions (Figure S1), 
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between two crystallographically independent cations (Figures S2 and S3), COSY 1H‒1H 
NMR spectra of 2 (Figures S4 and S5), UV‒vis spectra of H2L
2 and 4 (Figures S6 and S7), 
hydrogen bonding interactions in 1 (Table S1) and selected matrix elements for simulation of 
1H NMR spectra of H2L
1 and 2 (Table S2). Description of the assay for antiproliferative 
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Graphical Abstract 
 
The in vitro anticancer potency of ligand precursors H2L
1 and H2L
2 and [Ni(H2L
1)Cl]Cl (1), 
[Pd(H2L
1)Cl]Cl (2), [Cu(H2L
1)Cl]Cl (3) and [Ni(H2L
2)Cl]Cl (4) was studied in three human 
cancer cell lines (A549, CH1 and SW480). Clear-cut structure-activity relationships have 
been established. The metal ions exert marked effects in a divergent manner: copper(II) 
increases, whereas nickel(II) and palladium(II) decrease the cytotoxicity of the hybrids. The 
antiproliferative activity of H2L
1 and metal complexes 1−3 decreases in all three cell lines in 
the following rank order: 3 > H2L
1 > 1 > 2. 
 
 
